GlobeNewswire: HTG Molecular Diagnostics, Inc. Contains the last 10 of 241 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T13:20:33ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/05/18/2671826/0/en/HTG-to-Highlight-the-Advantages-of-its-Drug-Discovery-Engine-at-the-2023-BIO-International-Convention.html?f=22&fvtc=4&fvtv=24906HTG to Highlight the Advantages of its Drug Discovery Engine at the 2023 BIO International Convention2023-05-18T12:00:00Z<![CDATA[TUCSON, Ariz., May 18, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced that its management team will present the advantages of its proprietary drug discovery engine at the 2023 Biotechnology Innovation Organization (BIO) International Convention and will host in-person meetings during the remaining days of the June 5 – 8, 2023 event in Boston, MA.]]>https://www.globenewswire.com/news-release/2023/05/16/2669977/0/en/HTG-Highlights-the-Advantages-of-Its-Drug-Discovery-Engine.html?f=22&fvtc=4&fvtv=24906HTG Highlights the Advantages of Its Drug Discovery Engine2023-05-16T12:47:40Z<![CDATA[TUCSON, Ariz., May 16, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported achievement of another technical milestone in its drug discovery business.]]>https://www.globenewswire.com/news-release/2023/05/10/2666165/0/en/HTG-Molecular-Diagnostics-Reports-First-Quarter-2023-Results-and-Provides-Recent-Business-Highlights.html?f=22&fvtc=4&fvtv=24906HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business Highlights2023-05-10T21:51:27Z<![CDATA[TUCSON, Ariz., May 10, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported financial results for the quarter ended March 31, 2023 and provided recent drug discovery business highlights.]]>https://www.globenewswire.com/news-release/2023/04/25/2653828/0/en/HTG-Provides-Update-on-Drug-Discovery-Partnering-Initiative.html?f=22&fvtc=4&fvtv=24906HTG Provides Update on Drug Discovery Partnering Initiative2023-04-25T12:00:00Z<![CDATA[TUCSON, Ariz., April 25, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today provided an update on partnering discussions for its drug discovery business unit.]]>https://www.globenewswire.com/news-release/2023/04/18/2648947/0/en/HTG-Announces-Key-First-Quarter-Milestone-Achievements-for-Drug-Discovery.html?f=22&fvtc=4&fvtv=24906HTG Announces Key First Quarter Milestone Achievements for Drug Discovery2023-04-18T12:00:00Z<![CDATA[TUCSON, Ariz., April 18, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced the achievement of three significant drug discovery business milestones in the first quarter of 2023.]]>https://www.globenewswire.com/news-release/2023/04/06/2642508/0/en/HTG-Technology-Featured-in-Numerous-Scientific-Posters-at-the-AACR-Annual-Meeting-April-16-19.html?f=22&fvtc=4&fvtv=24906HTG Technology Featured in Numerous Scientific Posters at the AACR Annual Meeting April 16-192023-04-06T12:00:00Z<![CDATA[TUCSON, Ariz., April 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced there will be at least four scientific posters featuring its proprietary HTG EdgeSeq™ technology presented at the American Association for Cancer Research Annual Meeting (AACR) April 16-19 in Orlando, Florida.]]>https://www.globenewswire.com/news-release/2023/01/09/2585275/0/en/HTG-Provides-a-Year-End-Update-on-its-Drug-Discovery-Business-and-Attends-LifeSci-Partners-2023-Corporate-Access-Event.html?f=22&fvtc=4&fvtv=24906HTG Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access Event2023-01-09T13:33:37Z<![CDATA[TUCSON, Ariz., Jan. 09, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today provided an update on the progress of its drug discovery business unit, including the filing of a patent application directed towards its first therapeutics target, and announced that its management team will be hosting in-person meetings at the LifeSci Partners 2023 Corporate Access Event from January 9-11, 2023 in San Francisco, CA.]]>https://www.globenewswire.com/news-release/2023/01/06/2584405/0/en/HTG-Announces-Certain-Preliminary-2022-Unaudited-Financial-Results.html?f=22&fvtc=4&fvtv=24906HTG Announces Certain Preliminary 2022 Unaudited Financial Results2023-01-06T13:00:00Z<![CDATA[Preliminary full year 2022 unaudited revenue of $6.4 million]]>https://www.globenewswire.com/news-release/2022/12/28/2580196/0/en/HTG-Molecular-Diagnostics-Provides-Highlights-of-its-Second-Event-in-Drug-Discovery-KOL-Webcast-Series.html?f=22&fvtc=4&fvtv=24906HTG Molecular Diagnostics Provides Highlights of its Second Event in Drug Discovery KOL Webcast Series2022-12-28T13:00:00Z<![CDATA[TUCSON, Ariz., Dec. 28, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, provides here a summary of its second HTG Therapeutics key opinion leader (KOL) webinar: “The Role of RNA Profiling in Drug Discovery and Analysis,” hosted on Tuesday, December 13, 2022.]]>https://www.globenewswire.com/news-release/2022/12/23/2579253/0/en/HTG-Molecular-Diagnostics-Announces-Closing-of-a-10-Million-Public-Offering.html?f=22&fvtc=4&fvtv=24906HTG Molecular Diagnostics Announces Closing of a $10 Million Public Offering2022-12-23T21:05:00Z<![CDATA[TUCSON, Ariz., Dec. 23, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced the closing of its previously announced public offering of an aggregate of 1,290,322 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to 1,290,322 shares of common stock and Series A-2 warrants to purchase 1,290,322 shares of common stock, at a combined public offering price of $7.75 per share (or pre-funded warrant) and accompanying warrants. The Series A-1 warrants have an exercise price of $7.50 per share, are immediately exercisable and will expire five years from the date of issuance, and the Series A-2 warrants have an exercise price of $7.50 per share, are immediately exercisable and will expire twenty-four months from the date of issuance.]]>